Systemic sclerosis, also known as scleroderma, is a rare and complex autoimmune
connective-tissue disease. Once considered an untreatable and unpredictable condition …

Over 200 interstitial lung diseases, from ultra rare to relatively common, are recognised.
Most interstitial lung diseases are characterised by inflammation or fibrosis within the …

Importance Interstitial lung disease (ILD) consists of a group of pulmonary disorders
characterized by inflammation and/or fibrosis of the lung parenchyma associated with …

This expert group consensus statement emphasises the need for standardising the definition
of progressive fibrosing interstitial lung diseases (F-ILDs), with an accurate initial diagnosis …

Systemic sclerosis (SSc) is a rare autoimmune connective tissue disease with multi-organ
involvement, fibrosis and vasculopathy. Treatment in SSc, including early diffuse cutaneous …

Background Pirfenidone has been shown to slow disease progression in patients with
idiopathic pulmonary fibrosis (IPF). However, there are few treatment options for progressive …

Myofibroblasts are the construction workers of wound healing and repair damaged tissues
by producing and organizing collagen/extracellular matrix (ECM) into scar tissue. Scar tissue …

Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in
systemic sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial …

Abstract Background Systemic sclerosis (SSc) is a rare, complex, connective tissue disorder.
Interstitial lung disease (ILD) is common in SSc, occurring in 35–52% of patients and …

Objective We provide evidence‐based recommendations regarding the treatment of
interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases …